News · 26 weeks64+150%
2025-12-282026-06-21
Mix2990d
- Insider14(48%)
- SEC Filings7(24%)
- Other6(21%)
- Leadership1(3%)
- Offering1(3%)
Latest news
25 items- INSIDERCHIEF EXECUTIVE OFFICER Pickering Grant exercised 225 shares at a strike of $1.79 and sold $1,284,205 worth of shares (24,461 units at $52.50) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 474,703 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERPRESIDENT AND CFO Guggenhime Andrew exercised 10,000 shares at a strike of $5.35 and sold $530,000 worth of shares (10,000 units at $53.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECSEC Form 144 filed by Vaxcyte Inc.144 - Vaxcyte, Inc. (0001649094) (Subject)
- SECSEC Form 144 filed by Vaxcyte Inc.144 - Vaxcyte, Inc. (0001649094) (Subject)
- INSIDERDirector Paya Carlos V was granted 2,265 shares, increasing direct ownership by 49% to 6,856 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERDirector Brandicourt Olivier was granted 2,194 shares, increasing direct ownership by 88% to 4,699 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERDirector Furey John was granted 2,265 shares, increasing direct ownership by 74% to 5,306 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERDirector Lee Jacks was granted 2,265 shares, increasing direct ownership by 49% to 6,856 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERDirector Gilbert Halley E was granted 2,265 shares, increasing direct ownership by 22% to 12,481 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERDirector Loxam Teri was granted 2,265 shares, increasing direct ownership by 22% to 12,481 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERDirector Drapeau Anne S was granted 2,265 shares, increasing direct ownership by 22% to 12,481 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERDirector Lukatch Heath was granted 2,265 shares, increasing direct ownership by 13% to 19,481 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECVaxcyte Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Vaxcyte, Inc. (0001649094) (Filer)
- INSIDERCHIEF OPERATING OFFICER Wassil Jim sold $111,416 worth of shares (2,250 units at $49.52) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 158,494 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- PRVaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy AdultsFirst-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus Two-Stage, Dose-Escalation Study Designed with Primary Objective to Evaluate Safety and Tolerability and Secondary Objective to Assess Antigen-Specific Immune Responses Group A Strep Is Responsible for Approximately 800 Million New Cases of Illness and More Than 600,000 Deaths Annually Worldwide, with No Approved Vaccine and Significant Public Health Burden SAN CARLOS, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to p
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
- SECSEC Form 10-Q filed by Vaxcyte Inc.10-Q - Vaxcyte, Inc. (0001649094) (Filer)
- SECVaxcyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vaxcyte, Inc. (0001649094) (Filer)
- PRVaxcyte Reports First Quarter 2026 Financial Results and Provides Business UpdateEnrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed for VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose Expected Either Sequentially or Together by End of First Half of 2027 Company Expects to Initiate Phase 1 Adult Clinical Study for VAX-A1, a Vaccine Candidate to Prevent Disease Caused by Group A Strep, in
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
- INSIDERCHIEF OPERATING OFFICER Wassil Jim sold $127,870 worth of shares (2,250 units at $56.83) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 160,744 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECSEC Form DEFA14A filed by Vaxcyte Inc.DEFA14A - Vaxcyte, Inc. (0001649094) (Filer)
- SECSEC Form DEF 14A filed by Vaxcyte Inc.DEF 14A - Vaxcyte, Inc. (0001649094) (Filer)
- INSIDERSEC Form 4 filed by Cowan Elvia4 - Vaxcyte, Inc. (0001649094) (Issuer)
PCVX FAQ
7 questionsWhat does Vaxcyte Inc. do?
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020...Where does PCVX stock trade?
Vaxcyte Inc. (PCVX) is listed on NASDAQ.What sector and industry is PCVX in?
Vaxcyte Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Vaxcyte Inc. go public?
Vaxcyte Inc. (PCVX) completed its IPO in 2020.What are analysts saying about PCVX?
Vaxcyte Inc. has had 8 recent analyst actions on file. The most recent action was from Needham: Buy on 2026-01-07. Recent price targets cluster around $3800.00.What companies are similar to PCVX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PCVX side-by-side with any of them on Quantisnow.How can I track PCVX on Quantisnow?
Quantisnow aggregates Vaxcyte Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PCVX to receive live email and push alerts on every new disclosure.